Lifarizine

TargetMol
Product Code: TAR-T27830
Supplier: TargetMol
CodeSizePrice
TAR-T27830-1mg1mg£188.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27830-5mg5mg£352.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27830-10mg10mg£496.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27830-25mg25mg£760.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27830-50mg50mg£1,018.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27830-100mg100mg£1,348.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Lifarizine is a calcium and sodium channel antagonist. Lifarizine (RS-87476) shows neuroprotective efficacy in a simplified rat survival model of 2 vessel occlusion.
CAS:
119514-66-8
Formula:
C29H32N4
Molecular Weight:
436.603
Pathway:
Membrane transporter/Ion channel|Metabolism
Purity:
0.98
SMILES:
Cc1[nH]c(nc1CN1CCN(CC1)C(c1ccccc1)c1ccccc1)-c1ccc(C)cc1
Target:
Calcium Channel

References

1. Spedding M. Reasons why stroke trials underestimate the neuroprotective effects of drugs. Stroke. 2002 Jan;33(1):324-5. PubMed PMID: 11779937. 2. Mestre M, Djellas Y, Carriot T, Cavero I. Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics. Fundam Clin Pharmacol. 2000 Mar-Apr;14(2):107-17. PubMed PMID: 10796057. 3. Cramer WC, Toorop GP. Focal cerebral ischemia in the mouse: hypothermia and rapid screening of drugs. Gen Pharmacol. 1998 Feb;30(2):195-200. PubMed PMID: 9502174. 4. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 1997 Nov;49(5 Suppl 4):S66-9. Review. PubMed PMID: 9371155.